Wednesday, July 19, 2023 7:25:21 PM
Shorts here have nothing relevant to say ,
to do this one need some knowledge on the subject ..and they still posting that Leronlimab never finished any study meeting any endpoint ..
Hello , let’s only talk about HIV combo , when with 350 mg efficacy was 81% .. not one serious side effect .
The other 2 approved at the time drugs ..
—- Ibalizumab with 43% efficacy , and
—- Maraviroc with 45% .
They know nothing . So the only thing they doing on this MB is person attacks , and insults on EVERY long , and on some more then another .
Few shorts here behaving as a real stalkers .. they scary at times .
No , they have nothing smart to say , they know nothing smart , so don't expect it from them ..
All imo .
GLTA longs .
to do this one need some knowledge on the subject ..and they still posting that Leronlimab never finished any study meeting any endpoint ..
Hello , let’s only talk about HIV combo , when with 350 mg efficacy was 81% .. not one serious side effect .
The other 2 approved at the time drugs ..
—- Ibalizumab with 43% efficacy , and
—- Maraviroc with 45% .
They know nothing . So the only thing they doing on this MB is person attacks , and insults on EVERY long , and on some more then another .
Few shorts here behaving as a real stalkers .. they scary at times .
No , they have nothing smart to say , they know nothing smart , so don't expect it from them ..
All imo .
GLTA longs .
Bullish
Recent CYDY News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 01:40:20 PM
